|
Join us for a timely discussion of FDA's new technical guidance on submitting clinical trial datasets to evaluate the impact of immunogenicity on drug PK. @Joleen White will provide a brief overview, followed by an interactive panel and audience Q&A featuring perspectives from the FDA publication team ...
|